Table 1 Characteristics of the included studies
Trail | Country | Tranexamic acid group | Placebo group | ||||||
|---|---|---|---|---|---|---|---|---|---|
Number | Age (years) | Method | Follow-up | Number | Age (years) | Follow-up | |||
1 | Chakroun-Walha 2019 [11] | Tunisia | 96 | 44.0 ± 20.0 | VTA was administered as soon as possible, with a first dose of 1 g in 100 ml of normal saline in 10 min and then with a maintenance dose of 1 g per 500 ml of normal saline for 8 h | 28 days | 84 | 39 ± 18 | 28 days |
2 | CRASH-2 trial collaborators 2011 [10] | India and Colombia | 123 | 36.0 ± 14.0 | VTA was administered with the first dose of 1 g in 100 ml of normal saline in 10 min and then with a maintenance dose of 1 g per 1000 ml of normal saline for 8 h | 28 days | 126 | 37 ± 14 | 28 days |
3 | CRASH-3 trial collaborators 2019 [5] | UK | 4613 | 41.7 ± 19.0 | VTA was administered with the first dose of 1 g in 100 ml of normal saline over 10 min, followed by an intravenous infusion of 1 g over 8 h | 28 days | 4514 | 41.9 ± 19.0 | 28 days |
4 | Fakharian 2018 [12] | Iran | 74 | 42.3 ± 18.3 | VTA was administered with the first dose of 1 g in 100 ml of normal saline in 10 min and then with a maintenance dose of 1 g per 1000 ml of normal saline for 8 h | 3 months | 75 | 39.3 ± 18.1 | 3 months |
5 | Roberts 2013 [4] | UK | 10060 | 34.6 ± 14.1 | VTA (loading dose of 1 g of VTA infused over 10 min, followed by an intravenous infusion of 1 g over 8 h) | 28 days | 10,067 | 34.5 ± 14.4 | 28 days |
6 | Yutthakasemsunt 2013 [13] | Thailand | 120 | 34.8 ± 16.0 | VTA (loading dose of 1 g over 30 min followed by a maintenance dose of 1.0 g infused over 8 h) | 24–32 h | 118 | 34.1 ± 15.3 | 24–32 h |